QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:YMAB

Y-mAbs Therapeutics - YMAB Stock Forecast, Price & News

$4.55
-0.13 (-2.78%)
(As of 02/6/2023 04:10 PM ET)
Add
Compare
Today's Range
$4.51
▼
$4.75
50-Day Range
$4.18
▼
$5.18
52-Week Range
$2.94
▼
$20.48
Volume
170,746 shs
Average Volume
325,373 shs
Market Capitalization
$198.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Y-mAbs Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
207.7% Upside
$14.00 Price Target
Short Interest
Healthy
5.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Y-mAbs Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$5,879 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.73) to ($1.40) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

118th out of 1,027 stocks

Pharmaceutical Preparations Industry

49th out of 500 stocks

See Top Rated MarketRank™ Stocks Here
YMAB stock logo

About Y-mAbs Therapeutics (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

January 25, 2023 | marketbeat.com
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (YMAB)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
February 6, 2023 | benzinga.com
Y-mAbs Shareholder Action Reminder
February 6, 2023 | Investing Trends (Ad)
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
February 3, 2023 | benzinga.com
YMAB Investors Have Opportunity to Lead Y-mAbs Therapeutics, Inc. Securities Fraud Lawsuit
February 2, 2023 | finance.yahoo.com
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
February 1, 2023 | wsj.com
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Significant Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMAB
February 1, 2023 | wsj.com
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Significant Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMAB
February 1, 2023 | americanbankingnews.com
Y-mAbs Therapeutics (NASDAQ:YMAB) PT Raised to $13.00
February 6, 2023 | Investing Trends (Ad)
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
January 30, 2023 | americanbankingnews.com
Morgan Stanley Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) to Underweight
January 27, 2023 | wsj.com
Y-mAbs Shareholder Notice
January 27, 2023 | benzinga.com
Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.
January 27, 2023 | morningstar.com
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
January 27, 2023 | wsj.com
YMAB INVESTOR ALERT: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
January 25, 2023 | wsj.com
Y-mAbs Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
January 24, 2023 | benzinga.com
Y-mAbs Therapeutics, Inc. (YMAB) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Y-mAbs Therapeutics, Inc.
January 24, 2023 | wsj.com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 24, 2023 | wsj.com
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit -- YMAB
January 23, 2023 | benzinga.com
YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors Of a Class Action Lawsuit and Upcoming Deadline
January 23, 2023 | benzinga.com
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
January 23, 2023 | benzinga.com
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 21, 2023 | markets.businessinsider.com
INVESTOR DEADLINE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMAB
January 20, 2023 | technews.tmcnet.com
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)
January 20, 2023 | benzinga.com
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
January 20, 2023 | technews.tmcnet.com
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
January 19, 2023 | benzinga.com
Y-mAbs Investor Alert
January 19, 2023 | technews.tmcnet.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Company Calendar

Last Earnings
11/04/2021
Today
2/06/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:YMAB
CUSIP
N/A
CIK
1722964
Web
www.ymabs.com
Phone
(646) 885-8505
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+207.7%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,280,000.00
Net Margins
-307.75%
Pretax Margin
-307.75%
Return on Equity
-92.65%
Return on Assets
-74.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.16
Quick Ratio
3.97

Sales & Book Value

Annual Sales
$34.90 million
Price / Sales
5.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
1.10

Miscellaneous

Outstanding Shares
43,670,000
Free Float
34,668,000
Market Cap
$198.70 million
Optionable
Not Optionable
Beta
0.70

Key Executives

  • Thomas Gad
    President, Chief Executive Officer & Director
  • Joris Wiel Jan Wilms
    Chief Operating Officer & Senior Vice President
  • Bo Kruse
    CFO, Secretary. Treasurer & Executive VP
  • Torben Lund-Hansen
    Chief Technology Officer & Senior Vice President
  • Steen Lisby
    Chief Scientific Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













YMAB Stock - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price forecast for 2023?

11 brokerages have issued twelve-month target prices for Y-mAbs Therapeutics' stock. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they expect the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 207.7% from the stock's current price.
View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2023?

Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of the year. Since then, YMAB shares have decreased by 6.8% and is now trading at $4.55.
View the best growth stocks for 2023 here.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our YMAB earnings forecast.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.08. The firm earned $8.97 million during the quarter, compared to analyst estimates of $10.87 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 92.65% and a negative net margin of 307.75%. During the same quarter in the previous year, the firm earned ($0.82) earnings per share.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics issued an update on its FY 2022 earnings guidance on Monday, November, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $51.75 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Strs Ohio (0.25%), Rice Hall James & Associates LLC (0.20%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $4.55.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $198.70 million and generates $34.90 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

The company employs 148 workers across the globe.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.

This page (NASDAQ:YMAB) was last updated on 2/6/2023 by MarketBeat.com Staff